Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset-Reference-Cited by-同舟云学术

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset

Published:2018-02-21 Issue:4 Volume:48 Page:367-375
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Kiura Katsuyuki¹,Imamura Fumio²,Kagamu Hiroshi³,Matsumoto Shingo⁴,Hida Toyoaki⁵,Nakagawa Kazuhiko⁶,Satouchi Miyako⁷,Okamoto Isamu⁸,Takenoyama Mitsuhiro⁹,Fujisaka Yasuhito¹⁰,Kurata Takayasu¹¹,Ito Masayuki¹²,Tokushige Kota¹²,Hatano Ben¹²,Nishio Makoto¹³

Affiliation:

1. Okayama University Hospital, Okayama

2. Osaka International Cancer Institute, Osaka

3. Niigata University Medical and Dental Hospital, Niigata

4. National Cancer Center Hospital East, Kashiwa

5. Aichi Cancer Center, Nagoya

6. Kindai University Hospital, Osaka

7. Hyogo Cancer Center, Akashi

8. Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka

9. Kyusyu Cancer Center, Fukuoka

10. Osaka Medical College Hospital, Osaka

11. Kansai Medical University Hospital, Osaka

12. Novartis Pharma K.K., Tokyo

13. The Cancer Institute Hospital of JFCR, Tokyo, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/48/4/367/25090386/hyy016.pdf

Reference19 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

3. First-Line Crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;New Engl J Med,2014

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;New Engl J Med,2013

5. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers;Katayama;Sci Transl Med,2012

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27

2. Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review;Cancers;2023-10-11

3. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis;Cancer Medicine;2023-04-05

4. Renal cyst formation complicating ALK inhibitors;Journal of Onco-Nephrology;2023-02-09

5. Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer;Expert Review of Anticancer Therapy;2022-12-29